Epigenetics of lung cancer

Respirology

Volumn 11, Issue 4, 2006, Pages 355-365

  Bowman, Rayleen V ^a   Yang, Ian A ^a,b   Semmler, Annalese B T ^a   Fong, Kwun M ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b THE PRINCE CHARLES HOSPITAL   (Australia)

Author keywords

Hypermethylation; Hypomethylation HDAC; Non small cell lung cancer

Indexed keywords

4 N ACETYLDINALINE; 5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; AZACITIDINE; BORTEZOMIB; BUTYRIC ACID; CALPHOSTIN C; CARBOPLATIN; CPG OLIGODEOXYNUCLEOTIDE; CYTOSINE DERIVATIVE; DEPSIPEPTIDE; DNA; DOCETAXEL; EPIGALLOCATECHIN GALLATE; FR 901228; GEMCITABINE; HISTONE; HISTONE DEACETYLASE INHIBITOR; HYDRALAZINE; NUCLEOSIDE ANALOG; PACLITAXEL; PIVALOYLOXYMETHYL BUTYRATE; PROCAINE; S ADENOSYLMETHIONINE; S ADENOSYLMETHIONINE INHIBITOR; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT; ZEBULARINE;

BLADDER CANCER; CANCER CELL CULTURE; CANCER DIAGNOSIS; CHROMATIN; CHROMATIN STRUCTURE; CLINICAL TRIAL; DIAGNOSTIC VALUE; DNA HISTONE INTERACTION; DNA METHYLATION; DNA PACKAGING; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; EMBRYO DEVELOPMENT; EPIGENETICS; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; GENOME ANALYSIS; HEMATOLOGIC MALIGNANCY; HERITABILITY; HUMAN; LOW DRUG DOSE; LUNG CANCER; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MOLECULAR BIOLOGY; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; X CHROMOSOME INACTIVATION;

DNA METHYLATION; DNA, NEOPLASM; ENZYME INHIBITORS; EPIGENESIS, GENETIC; HISTONE DEACETYLASES; HUMANS; LUNG NEOPLASMS;

EID: 33744760804     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2006.00859.x     Document Type: Review

References (96)

1. Jemal A Murray T Ward E et al. Cancer statistics, 2005. CA Cancer J. Clin. 2005 55 : 10 30.
2. Ezzati M Lopez AD. Estimates of global mortality attributable to smoking in 2000. Lancet 2003 362 : 847 52.
3. Zhang H Cai B. The impact of tobacco on lung health in China. Respirology 2003 8 : 17 21.
4. Danaei G Vander Hoorn S Lopez AD Murray CJ Ezzati M. Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet 2005 366 : 1784 93.
5. Hanahan D Weinberg RA. The hallmarks of cancer. Cell 2000 100 : 57 70.
6. Karpinets TV Foy BD. Tumorigenesis: the adaptation of mammalian cells to sustained stress environment by epigenetic alterations and succeeding matched mutations. Carcinogenesis 2005 26 : 1323 34.
7. Jones PA Baylin SB. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 2002 3 : 415 28.
8. Robertson KD. DNA methylation and human disease. Nat. Rev. Genet 2005 6 : 597 610.
9. Schrump DS Nguyen DM. Targeting the epigenome for the treatment and prevention of lung cancer. Semin. Oncol. 2005 32 : 488 502.
10. Tycko B. Epigenetic gene silencing in cancer. J. Clin. Invest. 2000 105 : 401 7.
11. Feinberg AP Tycko B. The history of cancer epigenetics. Nat. Rev. Cancer 2004 4 : 143 53.
12. Vertino PM Spillare EA Harris CC Baylin SB. Altered chromosomal methylation patterns accompany oncogene-induced transformation of human bronchial epithelial cells. Cancer Res. 1993 53 : 1684 9.
13. Herman JG. Epigenetics in lung cancer: focus on progression and early lesions. Chest 2004 125 : 119S 22S.
14. Hutt JA Vuillemenot BR Barr EB et al. Life-span inhalation exposure to mainstream cigarette smoke induces lung cancer in B6C3F1 mice through genetic and epigenetic pathways. Carcinogenesis 2005 26 : 1999 2009.
15. Belinsky SA. Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer. Carcinogenesis 2005 26 : 1481 7.
16. Zochbauer-Muller S Fong KM Maitra A et al. 5′-CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res. 2001 61 : 3581 5.
17. Zochbauer-Muller S Fong KM Virmani AK Geradts J Gazdar AF Minna JD. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res. 2001 61 : 249 55.
18. Virmani AK Rathi A Zochbauer-Muller S et al. Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. J. Natl. Cancer Inst. 2000 92 : 1303 7.
19. Geradts J Fong KM Zimmerman PV Maynard R Minna JD. Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers. Clin. Cancer Res. 1999 5 : 791 800.
20. Heller G Fong KM Girard L et al. Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas. Oncogene 2006 25 : 959 68.
21. Kim JS Han J Shim YM Park J Kim DH. Aberrant methylation of H-cadherin (CDH13) promoter is associated with tumor progression in primary nonsmall cell lung carcinoma. Cancer 2005 104 : 1825 33.
22. Zochbauer-Muller S Fong KM Geradts J et al. Expression of the candidate tumor suppressor gene hSRBC is frequently lost in primary lung cancers with and without DNA methylation. Oncogene 2005 24 : 6249 55.
23. Suzuki M Hao C Takahashi T et al. Aberrant methylation of SPARC in human lung cancers. Br. J. Cancer 2005 92 : 942 8.
24. Izumi H Inoue J Yokoi S et al. Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers. Hum. Mol. Genet 2005 14 : 997 1007.
25. Digel W Lubbert M. DNA methylation disturbances as novel therapeutic target in lung cancer: preclinical and clinical results. Crit. Rev. Oncol. Hematol. 2005 55 : 1 11.
26. Belinsky SA. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat. Rev. Cancer 2004 4 : 707 17.
27. Frommer M McDonald LE Millar DS et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc. Natl. Acad. Sci. USA 1992 89 : 1827 31.
28. Laird PW. The power and the promise of DNA methylation markers. Nat. Rev. Cancer 2003 3 : 253 66.
29. Fukasawa M Kimura M Morita S et al. Microarray analysis of promoter methylation in lung cancers. J. Hum. Genet 2006 in press.
30. Paz MF Fraga MF Avila S et al. A systematic profile of DNA methylation in human cancer cell lines. Cancer Res. 2003 63 : 1114 21.
31. Esteller M Corn PG Baylin SB Herman JG. A gene hypermethylation profile of human cancer. Cancer Res. 2001 61 : 3225 9.
32. Belinsky SA Nikula KJ Palmisano WA et al. Aberrant methylation of p16 (INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc. Natl. Acad. Sci. USA 1998 95 : 11891 6.
33. Miyamoto K Ushijima T. Diagnostic and therapeutic applications of epigenetics. Jpn. J. Clin. Oncol. 2005 35 : 293 301.
34. Belinsky SA Klinge DM Dekker JD et al. Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin. Cancer Res. 2005 11 : 6505 11.
35. Ramirez JL Rosell R Taron M et al. 14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: the Spanish Lung Cancer Group. J. Clin. Oncol. 2005 23 : 9105 12.
36. Jones PA Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980 20 : 85 93.
37. Kantarjian HM O'Brien S Cortes J et al. Results of decitabine (5-aza-2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer 2003 98 : 522 8.
38. Issa JP Garcia-Manero G Giles FJ et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′- deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004 103 : 1635 40.
39. Daskalakis M Nguyen TT Nguyen C et al. Demethylation of a hypermethylated P15/INK4B gene in pa-tients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood 2002 100 : 2957 64.
40. Barletta JM Rainier S Feinberg AP. Reversal of loss of imprinting in tumor cells by 5-aza-2′-deoxycytidine. Cancer Res. 1997 57 : 48 50.
41. Cheng JC Matsen CB Gonzales FA et al. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J. Natl. Cancer Inst 2003 95 : 399 409.
42. Villar-Garea A Fraga MF Espada J Esteller M. Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. Cancer Res. 2003 63 : 4984 9.
43. Segura-Pacheco B Trejo-Becerril C Perez-Cardenas E et al. Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clin. Cancer Res. 2003 9 : 1596 603.
44. Fang MZ Wang Y Ai N et al. Tea polyphenol (-) -epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res. 2003 63 : 7563 70.
45. Costello JF Fruhwald MC Smiraglia DJ et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat. Genet. 2000 24 : 132 8.
46. Suzuki H Gabrielson E Chen W et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat. Genet. 2002 31 : 141 9.
47. Cameron EE Bachman KE Myohanen S Herman JG Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 1999 21 : 103 7.
48. Boivin AJ Momparler LF Hurtubise A Momparler RL. Antineoplastic action of 5-aza-2′-deoxycytidine and phenylbutyrate on human lung carcinoma cells. Anticancer Drugs 2002 13 : 869 74.
49. Belinsky SA Klinge DM Stidley CA et al. Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res. 2003 63 : 7089 93.
50. Weiser TS Guo ZS Ohnmacht GA et al. Sequential 5-Aza-2′- deoxycytidine-Depsipeptide FR901228 Treatment Induces Apoptosis Preferentially in Cancer Cells and Facilitates Their Recognition by Cytolytic T Lymphocytes Specific for NY-ESO-1. J. Immunother. 2001 24 : 151 61.
51. Miki K Shimizu E Yano S Tani K Sone S. Demethylation by 5-aza-2′-deoxycytidine (5-azadC) of p16INK4A gene results in downregulation of vascular endothelial growth factor expression in human lung cancer cell lines. Oncol. Res. 2000 12 : 335 42.
52. Olsson L Behnke O Sorensen HR. Modulatory effects of 5-azacytidine, phorbol ester, and retinoic acid on the malignant phenotype of human lung cancer cells. Int. J. Cancer 1985 35 : 189 98.
53. Lantry LE Zhang Z Crist KA et al. 5-Aza-2′-deoxycytidine is chemopreventive in a 4-(methyl-nitrosamino) -1-(3-pyridyl) -1-butanone-induced primary mouse lung tumor model. Carcinogenesis 1999 20 : 343 6.
54. Carr BI Rahbar S Doroshow JH et al. Fetal hemoglobin gene activation in a phase II study of 5,6-dihydro-5-azacytidine for bronchogenic carcinoma. Cancer Res. 1987 47 : 4199 201.
55. Momparler RL Bouffard DY Momparler LF Dionne J Belanger K Ayoub J. Pilot phase I-II study on 5-aza-2′-deoxycytidine (Decitabine) in patients with metastatic lung cancer. Anticancer Drugs 1997 8 : 358 68.
56. Schwartsmann G Schunemann H Gorini CN et al. A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer. Invest. New Drugs 2000 18 : 83 91.
57. Fahrner JA Eguchi S Herman JG Baylin SB. Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res. 2002 62 : 7213 18.
58. Kondo Y Shen L Issa JP. Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer. Mol. Cell Biol. 2003 23 : 206 15.
59. Schrump DS Nguyen DM Kunst TE et al. Phase I study of sequential deoxyazacytidine/depsipeptide infusion in patients with malignancies involving lungs or pleura. Clin. Lung Cancer 2002 4 : 186 92.
60. Eden A Gaudet F Waghmare A Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003 300 : 455.
61. Espada J Ballestar E Fraga MF et al. Human DNA methyltransferase 1 is required for maintenance of the histone H3 modification pattern. J. Biol. Chem. 2004 279 : 37175 84.
62. Wolf SF Migeon BR. Studies of X chromosome DNA methylation in normal human cells. Nature 1982 295 : 667 71.
63. Fraga MF Uriol E Borja Diego L et al. High-performance capillary electrophoretic method for the quantification of 5-methyl 2′-deoxycytidine in genomic DNA: application to plant, animal and human cancer tissues. Electrophoresis 2002 23 : 1677 81.
64. Kawasaki H Taira K. Induction of DNA methylation and gene silencing by short interfering RNAs in human cells. Nature 2004 431 : 211 17.
65. Morris KV Chan SW Jacobsen SE Looney DJ. Small interfering RNA-induced transcriptional gene silencing in human cells. Science 2004 305 : 1289 92.
66. de Ruijter AJ van Gennip AH Caron HN Kemp S van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 2003 370 : 737 49.
67. Strachan T Read AP. Human Molecular Genetics, 3rd edn. Garland Science, New York, 2004.
68. Yang XJ Gregoire S. Class II histone deacetylases: from sequence to function, regulation, and clinical implication. Mol. Cell Biol. 2005 25 : 2873 84.
69. Dokmanovic M Marks PA. Prospects: histone deacetylase inhibitors. J. Cell Biochem. 2005 96 : 293 304.
70. Sengupta N Seto E. Regulation of histone deacetylase activities. J. Cell Biochem. 2004 93 : 57 67.
71. Minucci S Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 2006 6 : 38 51.
72. Kaneda R Toyota M Yamashita Y et al. High-throughput screening of genome fragments bound to differentially acetylated histones. Genes Cells 2004 9 : 1167 74.
73. Toh Y Ohga T Endo K et al. Expression of the metastasis-associated MTA1 protein and its relationship to deacetylation of the histone H4 in esophageal squamous cell carcinomas. Int. J. Cancer 2004 110 : 362 7.
74. Shetty S Graham BA Brown JG et al. Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1. Mol. Cell Biol. 2005 25 : 5404 16.
75. Zhu P Martin E Mengwasser J Schlag P Janssen KP Gottlicher M. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 2004 5 : 455 63.
76. Sasaki H Moriyama S Nakashima Y et al. Histone deacetylase 1 mRNA expression in lung cancer. Lung Cancer 2004 46 : 171 8.
77. Osada H Tatematsu Y Saito H Yatabe Y Mitsudomi T Takahashi T. Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. Int. J. Cancer 2004 112 : 26 32.
78. Bartling B Hofmann HS Boettger T et al. Comparative application of antibody and gene array for expression profiling in human squamous cell lung carcinoma. Lung Cancer 2005 49 : 145 54.
79. Ito K Ito M Elliott WM et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N. Engl. J. Med. 2005 352 : 1967 76.
80. Park JM Lee GY Choi JE et al. No association between polymorphisms in the histone deacetylase genes and the risk of lung cancer. Cancer Epidemiol. Biomarkers Prev. 2005 14 : 1841 3.
81. Mukhopadhyay NK Gordon GJ Maulik G et al. Histone deacetylation is directly involved in desilencing the expression of the catalytic subunit of telomerase in normal lung fibroblast. J. Cell Mol. Med. 2005 9 : 662 9.
82. Bartova E Pachernik J Harnicarova A et al. Nuclear levels and patterns of histone H3 modification and HP1 proteins after inhibition of histone deacetylases. J. Cell Sci. 2005 118 : 5035 46.
83. El-Khoury V Gomez D Liautaud-Roger F Trussardi-Regnier A Dufer J. Effects of the histone deacetylase inhibitor trichostatin A on nuclear texture and c-jun gene expression in drug-sensitive and drug-resistant human H69 lung carcinoma cells. Cytometry A 2004 62 : 109 17.
84. Kodani M Igishi T Matsumoto S et al. Suppression of phosphatidylinositol 3-kinase/Akt signaling pathway is a determinant of the sensitivity to a novel histone deacetylase inhibitor, FK228, in lung adenocarcinoma cells. Oncol. Rep. 2005 13 : 477 83.
85. Choi YH. Induction of apoptosis by trichostatin A, a histone deacetylase inhibitor, is associated with inhibition of cyclooxygenase-2 activity in human non-small cell lung cancer cells. Int. J. Oncol. 2005 27 : 473 9.
86. Doi S Soda H Oka M et al. The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells. Mol. Cancer Ther. 2004 3 : 1397 402.
87. Mayo MW Denlinger CE Broad RM et al. Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kappa B through the Akt pathway. J. Biol. Chem. 2003 278 : 18980 9.
88. Rundall BK Denlinger CE Jones DR. Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer. Surgery 2005 138 : 360 7.
89. Maxhimer JB Reddy RM Zuo J Cole GW Schrump DS Nguyen DM. Induction of apoptosis of lung and esophageal cancer cells treated with the combination of histone deacetylase inhibitor (trichostatin A) and protein kinase C inhibitor (calphostin C). J. Thorac. Cardiovasc. Surg. 2005 129 : 53 63.
90. Loprevite M Tiseo M Grossi F et al. In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines. Oncol. Res. 2005 15 : 39 48.
91. Sonnemann J Gange J Kumar KS Muller C Bader P Beck JF. Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines. Invest. New Drugs 2005 23 : 99 109.
92. Denlinger CE Rundall BK Jones DR. Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species. J. Thorac Cardiovasc. Surg. 2004 128 : 740 8.
93. Bevins RL Zimmer SG. It's about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells. Cancer Res. 2005 65 : 6957 66.
94. Nome RV Bratland A Harman G Fodstad O Andersson Y Ree AH. Cell cycle checkpoint signaling in-volved in histone deacetylase inhibition and radiation-induced cell death. Mol. Cancer Ther. 2005 4 : 1231 8.
95. Pauer LR Olivares J Cunningham C et al. Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors. Cancer Invest. 2004 22 : 886 96.
96. Reid T Valone F Lipera W et al. Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer 2004 45 : 381 6.